- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
OsimertinibOsimertinib as monotherapy is indicated for: ∙ the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. ∙ the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations. ∙ the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.